YubaNet.com
Saturday, September 20 2014

            We Deliver News to the Sierra
News Fire News spacer Latest News spacer Regional News spacer California News spacer USA News spacer World News spacer Op-Ed spacer Enviro News spacer Sci Tech News spacer Life spacer Odd News spacer Cartoons spacer
Features The Calendar features features Weather features Sierra NightSky features features features Road Conditions features Home spacer
Life
 

Chairmen Waxman and Stupak Request Study Data for Vytorin


    Google+    

By: Chairman Henry A. Waxman

Feb. 19, 2009 - Today Chairman Waxman and Subcommittee on Oversight and Investigations Chairman Stupak wrote to Schering-Plough and Merck, the companies developing Vytorin, to request further information regarding two studies on the drug. The monitoring boards for the studies released their data to Schering-Plough and Merck before the conclusion of the studies upon the request of those companies. The text of the letter follows:

Dear Mr. Hassan and Mr. Clark:

The Committee on Energy and Commerce and its Subcommittee on Oversight and Investigations are continuing an investigation into the safety and effectiveness of Vytorin, a prescription drug manufactured jointly by Schering-Plough and Merck.

On September 5, 2008, your counsel provided a briefing to Committee staff on a clinical trial called the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial. Your counsel stated that in January 2008, the Data Safety Monitoring Board for this trial, which is responsible for ensuring the safety of patients participating in the trial, requested that the Data Safety Monitoring Boards for two other large, ongoing Vytorin trials "unblind," or release, their study data prior to the conclusion of the studies. According to your counsel, the Data Safety Monitoring Boards for both of those trials ? the Study of Heart and Renal Protection (SHARP) trial and the Examining Outcomes in Subjects with Acute Coronary Syndrome: Vytorin vs. Simvastatin (IMPROVE-IT) trial ? agreed to do so.

We are writing to request information about the decisions by the Data Safety Monitoring Boards to unblind the interim data from the SHARP and IMPROVE-IT trials. Accordingly, we request that Schering-Plough, Merck, and the joint venture of Schering-Plough and Merck produce the following documents and information by March 6, 2009:

1. The names, affiliations, and current contact information for all members of the Data Safety Monitoring Boards for the SEAS, SHARP, and IMPROVE-IT trials;

2. The names, affiliations, and current contact information for all members of the steering committees for the SEAS, SHARP, and IMPROVE-IT trials;

3. All documents relating to Institutional Review Board (IRB) approval and any subsequent IRB deliberations relating to the SEAS trial;

4. All minutes of Data Safety Monitoring Board meetings for the SEAS trial;

5. All communications relating to the SEAS trial between or among:

a. Any members of the SEAS trial's Data Safety Monitoring Board;

b. Any member of the SEAS trial's Data Safety Monitoring Board and any members of the SEAS, SHARP, or IMPROVE-IT steering committees;

c. Any member of the SEAS trial's Data Safety Monitoring Board and any investigators for the SEAS, SHARP, or IMPROVE-IT trials;

d. Any member of the SEAS trial's Data Safety Monitoring Board and any officers or employees of Merck, Schering-Plough, or the Merck/Schering-Plough joint venture;

6. All documents relating to the submission of the SEAS manuscript to the New England Journal of Medicine; and

7. All minutes of Data Safety Monitoring Board meetings for the SHARP and IMPROVE-IT trials no later than two weeks after the completion of those trials.

We request that Schering-Plough, Merck, and the joint venture of Schering-Plough and Merck retain without alteration, until further notice, all minutes, records, communications, and other documents relating to the Data Safety Monitoring Boards for the SEAS, SHARP, and IMPROVE-IT trials.

An attachment to this letter provides additional information on how to respond to the Committee's request. If you have any questions regarding this request, please contact Paul Jung of the Committee staff at (202) 226-2424.

Sincerely,


Henry A. Waxman, Chairman
Bart Stupak, Chairman Subcommittee on Oversight and Investigations

 

Help us bring you more news. Be a real reader: Support YubaNet

By submitting a comment you consent to our rules. You must use your real first and last name, not a nickname or alias. A comment here is just like a letter to the editor or a post on Facebook. Thank you.

 

Latest Headlines

Life

Clownfish That Inspired Finding Nemo Closer to Endangered Species Act Protection

The Disappearing Spoon author Sam Kean takes on the megalodon myth

The HPV vaccine could save the life of your child

Survival Entertainment, Friend or Foe? An exclusive interview with Cody Lundin

Ninety-Four Years Ago Today Women Won the Right to Vote; Newly Discovered Letters Will Help Show How

Consumer Federation of America: Insurance Companies May be Raising Your Rates for No Reason

World Dog Day: Keep your dog healthy in mind and body

Humans Need Not Apply (Video)

New Book, "Capitalism v. Democracy' Exposes the Death of Campaign Finance Reform -- Blame It on the Supreme Court

This Labor Day, Americans Urged to Save Wildlife, Keep Meat Off the Grill


More

 

 

 

 

NEWS . Fire News . Latest . Regional . California . USA . World . Op-Ed . Enviro . Sci/Tech . Life . Odd News . Cartoons
FEATURES . The Calendar .Weather . Sierra NightSky . Horoscope . Road Conditions
YubaNet.com . Advertising. About Us . Support YubaNet . Contact Us . Terms of Use . Privacy

YubaNet.com © 1999-2014
Nevada City, California (530) 478-9600